Aerovate Q3 net loss widens to $13.6M; trial enrollment delays, cash runway to 2H25

Jade Biosciences, Inc.

2022-Q3 EPS reported -$1.49

Net loss $13.6M for Q3 2022 vs $6.2M in Q3 2021; R&D expenses tripled to $10.8M.
Cash and investments $142.6M as of Sep 30, 2022, down from $167.4M at Dec 31, 2021; runway into 2H25.
IMPAHCT Phase 2b/3 trial enrollment delayed; topline data expected Q4 2023 or Q1 2024.
Expanded IP with two new U.S. patents (11,413,289 and 11,464,776) issued; notice of allowance for another.
Sanjeev Khindri joined as SVP Clinical Development; brings respiratory and PAH experience.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Jade Biosciences, Inc. reported the quarter ended September 30, 2022 results: net income $13.6 million.

Period: the quarter ended September 30, 2022
Net income: $13.6 million
Result: reported results

Exact text from the filing

On November 14, 2022, Aerovate Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Jade Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-017582

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.